First,
our proteomics platform continues to yield novel cancer targets that
have been the focus of several partnerships for drug discovery and
development, allowing us to advance them cost effectively.com, or by telephoning
800.
Applied Biosystems, Celera, Celera Diagnostics, Celera Discovery
System, and Celera Genomics are trademarks of Applera Corporation or
its subsidiaries in the U.

(1)Johnstone, RW.

manually kinetics

ST. MetaDrug(TM ) will be useful for preclinical assessment of
molecules and their predicted properties.
MetaCore (TM) features a comprehensive set of maps, pathways and networks
for almost all known human proteins; parsers for importing data from all major
microarray platforms, SAGE, proteomics and metabolomics data;
seven proprietary network building algorithms; flexible visualization and data
exchange tools.

About GeneGo
GeneGo is a Michigan-based company developing systems biology technology
for life science research. "We
anticipate that we will utilize the insights we have gained from the
identification of potential biomarkers of efficacy to design and
implement our clinical trials, the first of which is planned to assess
the safety and pharmacokinetics of CRA-024781 in a dose escalation
study, at a projected cost of less than $3 million. Celera Diagnostics, a 50 /50 joint
venture between Applied Biosystems and Celera Genomics, is focused on
discovery, development , and commercialization of diagnostic products.

nucleic toldo

Histone deacetylation is carried out by a family of related HDAC
enzymes. Secondly,
and with today's achievement of filing for an IND with the FDA , our
small molecule capability and pipeline of compounds is now
sufficiently mature to look to partner and capitalize on this asset.

nucleic polymerase

MetaDrug(TM) features maps, pathways and networks for human proteins
related to ADME/Tox; a database of small molecules with kinetic data for human
drug metabolizing enzymes, proprietary algorithms for rule-based metabolite
prediction, highlighting of reactive metabolites , > 40 QSAR models for
ADME/Tox properties, descriptors relevant to ADME parsers for importing data
from all major microarray platforms, SAGE, proteomics and metabolomics data;
two proprietary network building algorithms; flexible visualization and data
exchange tools.
These may be identified by the use of forward-looking words or phrases
such as "believe," "expect," "intend," "should," and "planned," among
others.S.

enzyme chromatogram

Information about Applera Corporation, including reports and other
information filed by the company with the Securities and Exchange
Commission, is available at www. In order to comply with the terms of the safe harbor,
Applera Corporation notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements.

enzyme transduction

JOSEPH, Mich.
MetaDrug(TM ) is a pioneering Systems - ADME/Tox platform which combines
software for predicting metabolites and over 40 ADME/Tox properties with
visualization and analysis of toxicogenomics and metabolomics data . Celera
Genomics recently reported data at the American Association for Cancer
Research (AACR ) meeting in April 2005, showing the efficacy of
CRA-024781 as an HDAC inhibitor in xenograft cancer models.
The Applied Biosystems Group (NYSE:ABI) serves the life science
industry and research community by developing and marketing
instrument-based systems, consumables, software, and services .762.com

Forward-Looking Statements

Certain statements in this press release are forward -looking. Histone-Deactylase Inhibitors: Novel drugs for
the treatment of cancer.

3700 phylogenetic

GeneGo's second product, MetaDrug(TM), assists pharmaceutical scientists with
the prediction of metabolites and their likely toxicity in humans.celera. and/or certain other countries.

sequencers 3730

Sean Ekins, Vice
President, Computational Biology. For more
information, please visit the company's Web site at http://www. "While the
Online /Information Business was important to Celera Genomics in its
initial years, it is no longer strategically relevant and has been a
source of cash consumption, estimated to be approximately $7 million
for fiscal 2005, since many of the subscriptions were prepaid.

chromatogram molecule

Ultimately both products
enable the prediction of interactions of a small molecule with both xenobiotic
and endogenous metabolism, regulation and cellular signaling."
"Celera Genomics now has three important strategic assets.
Finally, Celera Diagnostics, a 50-50 joint venture with Applied
Biosystems, is generating substantial product sales and making
important discoveries for incorporation into future new products," Ms
Ordonez added .7 billion during fiscal 2004.

genomes chromatogram

MetaDrug(TM) is also complimentary
with MetaCore(TM) enabling researchers to build and analyze protein-protein,
protein-ligand and genetic interaction networks using GeneGo 's comprehensive
databases of human biology and active chemistry. Pending
clearance by the FDA , Celera Genomics plans to initiate Phase 1
clinical trials.

Category also includes education software for biochemistry or molecular biology.

polymerase molecule

The user can therefore interpret both chemical and biological data in
the context of the whole organism, merging predictions with empirical data
when available . "With the anticipated discontinuation of the
Online/Information Business, Celera Genomics is now in a position to
focus its efforts on its most substantial opportunities while managing
its use of cash."
Celera Genomics has another compound, a Cathepsin K inhibitor, in
a Phase I clinical trial as a potential treatment for osteoporosis. It is also seeking
to advance therapeutic antibody and selected small molecule drug
programs in collaboration with global technology and market leaders . These risks and uncertainties include but are not limited
to: (1) Celera Genomics' unproven ability to discover, develop, or
commercialize proprietary therapeutic products; (2) the risk that
clinical trials of products that Celera Genomics does discover and
develop will not proceed as anticipated or may not be successful, or
that such products will not receive required regulatory clearances or
approvals; (3) the uncertainty that Celera Genomics' products will be
accepted and adopted by the market, including the risk that that these
products will not be competitive with products offered by other
companies, or that users will not be entitled to receive adequate
reimbursement for these products from third party payors such as
private insurance companies and government insurance plans; (4)
uncertainty of the availability to Celera Genomics of intellectual
property protection, limitations on their ability to protect trade
secrets, and the risk to them of infringement claims; and (5) other
factors that might be described from time to time in Applera
Corporation's filings with the Securities and Exchange Commission.

Software aimed primarily for use in biochemistry or molecular biology research .

visualizing sequencing

Inhibition of these enzymes causes changes to chromatin
structure and to gene expression patterns , which results in the
inhibition of proliferation of cancer cells, and induction of
apoptosis . Applera Corporation.

polymerase sequencing

, GeneGo, Inc.

visualizing biochemistry

Celera Genomics published the first three-dimensional
structure of an HDAC enzyme in July 2004, and this information has
been used to aid the design of a series of novel HDAC inhibitors. This followed a multi-year collaboration with Merck
to develop small molecule inhibitors of Cathepsin K, which was
initiated in November 1996.

polymerase 3700

, A leading systems
biology company, today announced the official launch of MetaDrug(TM) V1.

Celera Genomics Files Investigational New Drug Application for Novel HDAC Inhibitor CRA-024781

This compound is partnered with Merck , and has been in clinical trials
since July 2004. These forward-looking statements are based on Applera
Corporation's current expectations. The Private Securities Litigation
Reform Act of 1995 provides a "safe harbor" for such forward-looking
statements.

biochemistry domix

Food and Drug Administration (FDA) for
CRA -024781, a novel histone deacetylase (HDAC) inhibitor., Chief Scientific Officer of Celera Genomics.

applera. All
information in this press release is as of the date of the release,
and Applera does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

enzyme rnai

0.
MetaDrug(TM) can be used as a stand alone product or together with
MetaCore (TM), GeneGo's flagship analytical platform. MetaDrug(TM) contains an extensive, expert
curated database of small molecule content related to human drug metabolism,
algorithms for predicting and prioritization of metabolites, the ability to
highlight reactive metabolites and the most extensive set of predictive
ADME/Tox models available.

Copyright (C) 2005.

transduction visualizing

domix visualizing

com.
"We're pleased with the progress we 've made in advancing
CRA-024781 through its preclinical experiments to this point," said
Robert Booth, Ph."
"Today's accomplishment reflects Celera's successful transition
from sequencing the human genome and selling data to focusing on the
realization of downstream value in therapeutics and diagnostics," said
Kathy Ordonez, President of Celera Genomics. Applied
Biosystems is headquartered in Foster City, CA, and reported sales of
$1.

molecule biologist

S. In
addition, it was demonstrated that the measurement of tubulin and
histone acetylation can be used to monitor the pharmacodynamic effects
of CRA-024781 in vivo. The Celera
Genomics Group is engaged principally in the discovery and development
of targeted therapeutics for cancer, autoimmune and inflammatory
diseases. Celera Genomics is leveraging its proteomic, bioinformatic,
and genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics.

workbench genomes

GeneGo Launches MetaDrug(TM) for Systems - ADME /Tox

"MetaDrug(TM) is the first commercial product that merges ADME/Tox
predictions in human with systems biology," said Dr. GeneGo's first product, MetaCore, is an original
computational platform for integration and expert analysis of different kinds
of experimental data (mRNA expression , proteomics, metabolites, siRNA and
other phenotypic data) and relevant active chemistry (metabolites , drugs,
other xenobiotics) within the framework of biological pathways and networks. Nature Reviews Drug Discovery, 2002,
1:287-299.

3730 ligand

Customers use these tools to analyze nucleic acids (DNA and RNA ),
small molecules, and proteins to make scientific discoveries, develop
new pharmaceuticals, and conduct standardized testing.

domix sequencing

MetaDrug(TM) also enables analysis of
toxicogeneomics data that can be visualized on networks and on static pathways
maps.

Business Editors/Health/Medical Writers
BIOWIRE2K

ROCKVILLE, Md.----

Filing of First Unpartnered Compound Signifies Celera 's Transformation
From Selling Data to Focusing on the Realization of Downstream Value
in Targeted Medicine

Celera Genomics (NYSE:CRA), an Applera Corporation business, today
announced that it has submitted an Investigational New Drug (IND)
application to the U. All Rights Reserved.

kinetics insilico

genego .

MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are the trademarks of GeneGo,
Inc.
HDAC inhibitors target HDAC enzymes and inhibit the proliferation
of cancer cells and induce cancer cell death, or apoptosis(1).D.6923.

manually workbench

About Celera Genomics and Applera Corporation

Applera Corporation consists of two operating groups. Information about Celera Genomics is available at
www.